Anteris Technologies Global Corp.·Healthcare
Anteris Technologies Global Corp., a structural heart company, discovers, develops, and commercializes medical devices to enhance the quality of life for patients with aortic stenosis. Its lead product candidate is the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also devlops ADAPT anti-calcification tissue, an anti-calcification preparation that transforms xenograft tissue into durable bioscaffolds that are used to mimic human tissue for surgical repair in multiple settings, including aortic valve replacement; and ComASUR delivery system, a physician-developed balloon expandable delivery system that contains a reinforced steerable catheter for a precise deflection through the heart anatomy in a controlled manner to avoid damage to the aorta. Anteris Technologies Global Corp. was incorporated in 1999 and is based in Toowong, Australia.
Healthcare
Medical - Devices
136
2024-12-13
0.55

Glaukos (NYSE: GKOS - Get Free Report) and Anteris Technologies Global (NASDAQ: AVR - Get Free Report) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, dividends, profitability, valuation and earnings. Volatility and Risk Glaukos has a beta of

Cardiovascular disease may be one of medicine’s oldest battlegrounds, but some of its most important technologies are still evolving — and not always as...

Tilray Inc (NASDAQ:TLRY) earned a repeat ‘Buy’ rating from Jefferies analysts after what it described as a solid third quarter earnings report, pointing to...

Foundayo launches on April 6 at the same price as Novo's pill, threatening to reshape the $50 billion obesity drug market before Novo's first-quarter...

The forex market now turns over $9.6 trillion every single day. That figure, confirmed by the Bank for International Settlements in its 2025 Triennial...

Anteris Technologies Global (NASDAQ: AVR) CEO and founder Wayne Paterson discussed the company's DurAVR transcatheter aortic valve replacement (TAVR) program, recent clinical visibility, and the company's approach to market development during a conversation that touched on product design, tissue science, reimbursement, and longer-term interest in heart failure care pathways. Clinical interest and a "total disease management"